Evaluating ADA Assay Sensitivity in the Presence of High Drug Levels

Anti-drug antibody (ADA) assays are essential in developing and monitoring biological therapies. These assays help identify immune responses that might neutralize drugs’ therapeutic effects or cause adverse reactions. One of the significant challenges in ADA testing is evaluating assay sensitivity in the presence of high drug levels. This blog will explore the importance of ADA assays, the impact of high drug levels on assay sensitivity, and strategies to optimize these assays for accurate and reliable results.

Understanding ADA Assays and Their Importance

ADA assays detect antibodies that the immune system produces against therapeutic drugs. These antibodies can neutralize the drug’s efficacy or cause adverse reactions, making ADA assays critical for ensuring drug safety and effectiveness. ADA testing helps understand the immunogenicity of biological medicines, enabling the development of strategies to mitigate adverse immune responses¹.

Overview of Drug Levels and Their Impact on Assay Sensitivity

High levels of therapeutic drugs in patient samples can interfere with ADA detection. This interference occurs because the drug can mask or bind to the antibodies, making them undetectable by the assay. Consequently, high drug levels can reduce the sensitivity of ADA assays, leading to false-negative results and underestimating the immunogenic response².

What is ADA Assay Sensitivity?

ADA assay sensitivity refers to the assay’s ability to detect low concentrations of anti-drug antibodies in the presence of the drug. High sensitivity is crucial for early detection of immune responses, ensuring timely interventions and adjustments in therapy². Unlike bioanalytical assays that aid in evaluating pharmacokinetics or toxicokinetics, immunogenicity testing involves calculating cut points to identify (screen), confirm (specificity), and assess titer responses in animals and humans⁴. A sensitive ADA assay can accurately measure the immunogenic response even when the drug concentration is high, providing a more comprehensive understanding of the drug’s impact on the immune system³.

How High Drug Levels Affect ADA Assays

High drug levels can significantly affect the accuracy and reliability of ADA assays. When the drug concentration in the sample is high, it can bind to the ADA, forming drug-ADA complexes not detectable by the assay^2,5. This binding reduces the free ADA available for detection, leading to false-negative results. High drug levels can also interfere with the assay’s binding sites, reducing sensitivity^3,5.

Challenges in ADA Testing with High Drug Levels

Several challenges arise when testing for ADA in the presence of high drug levels. These include:

Interference: High drug levels can mask ADA, making them undetectable.

Sensitivity: Balancing assay sensitivity to detect low levels of ADA while avoiding false positives.

Specificity: Ensuring the assay accurately distinguishes ADA from other antibodies or proteins in the sample.

Validation: Rigorous validation is needed to confirm the assay’s performance in high drug levels.

Importance of ADA Assay Validation in Drug Development

Validation is a crucial step in the development of ADA assays. It ensures the assay meets predefined performance criteria, including sensitivity, specificity, accuracy, and robustness. Validating ADA assays involves extensive testing to confirm that they can reliably detect ADA in varying drug concentrations. This process is essential for regulatory approval and ensuring biologic drugs’ safety and efficacy^6,7.

Strategies to Optimize ADA Assays for Greater Accuracy

Several strategies can be employed to optimize ADA assays and improve their accuracy in the presence of high drug levels:

Sample Dilution: Diluting samples can reduce drug interference, making it easier to detect ADA.

Acid Dissociation: Using acid to dissociate drug-ADA complexes can increase the availability of free ADA for detection².

High Ionic Strength Dissociation: Using high ionic strength dissociation using MgCl₂ to attain high drug tolerance while maintaining the structural integrity of ADA has shown improved drug tolerance and higher S/N ratios⁵.

Competitive Assays: Employing competitive binding assays can help differentiate between free ADA and drug-bound ADA.

Blocking Agents: Adding blocking agents can prevent the drug from interfering with ADA detection.

Comparison of the influence of High Ionic strength dissociation on signal generation by anti-drug antibody and soluble target in ADA assays⁵.

Role of Drug Interference in ADA Assays and How to Mitigate It

Drug interference is a significant challenge in ADA assays, but several techniques can mitigate its impact:

Acid/MgCl₂ Treatment: Treating samples with acid or MgCl₂ can dissociate drug-ADA complexes, freeing ADA for detection^1,5.

Assay Design: Designing assays to include steps that minimize drug interference can improve accuracy^1,2.

Alternative Assay Formats: Using different assay formats, such as bridging or competitive assays, can reduce the impact of drug interference³.

High-Affinity Reagents: Employing high-affinity reagents can improve the assay’s ability to detect ADA in high drug levels².

Conclusion

Evaluating ADA assay sensitivity in high drug levels is critical for ensuring the accuracy and reliability of immunogenicity testing^2,5. By understanding the challenges and employing strategies to mitigate drug interference, researchers can develop robust ADA assays that provide valuable insights into the immune response to biological therapies. Continued advancements in assay technology and validation methods will play a crucial role in the safe and effective development of new therapeutic agents.

References:

1. Louise Jorgensen. “Anti-drug antibody analysis in non-clinical samples.” – EBF Open Symposium, Barcelona 2019.  https://www.e-b-f.eu/wp-content/uploads/2019/12/bcn2019-34-Louise-Joergensen-NovoNordisk.pdf
2. Zhandong Don Zhong, Adrie3nne Clements-Egan, et al. “Drug Target Interference in Immunogenicity Assays: Recommendations and Mitigation Strategies.” AAPS J. 2017 Nov;19(6):1564-1575.  https://pubmed.ncbi.nlm.nih.gov/29063411/Gopi
3. Shankar, Charles Pendley, Katheryn Stein. “A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs.” Nat Biotechnol. 2007 May;25(5):555-6. https://pubmed.ncbi.nlm.nih.gov/17483842/
4. Devanarayan, V. et al. “Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.” AAPS Journal (2017). https://pubmed.ncbi.nlm.nih.gov/28733862/
5. Alexander Pohlere, Cordula Jany, et al. “High ionic strength dissociation assay reduces dimeric target interference in immunogenicity testing.” Bioanalysis, June 2023:15(12). https://www.researchgate.net/publication/371639007_High_ionic_strength_dissociation_assay_reduces_dimeric_target_interference_in_immunogenicity_testing#fullTextFileContent
6. AEMA, “Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins.” (2017). https://www.ema.europa.eu/en/immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-scientific-guideline
7. FDA, “Immunogenicity Testing of Therapeutic Protein Products — Developing and Validating Assays for Anti-Drug Antibody Detection.” (2019). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug